Aurobindo Pharma surges on receiving USFDA approval for Amoxicillin for Oral Suspension

17 Sep 2014 Evaluate

Aurobindo Pharma is currently trading at Rs. 863.75, up by 9.45 points or 1.11% from its previous closing of Rs. 854.30 on the BSE.

The scrip opened at Rs. 874.00 and has touched a high and low of Rs. 880.00 and Rs. 857.10 respectively. So far 63,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 908.00 on 16-Sep-2014 and a 52 week low of Rs. 171.00 on 17-Sep-2013.

Last one week high and low of the scrip stood at Rs. 908.00 and Rs. 848.00 respectively. The current market cap of the company is Rs. 25,158.00 crore.

The promoters holding in the company stood at 54.34% while Institutions and Non-Institutions held 35.32% and 10.34% respectively.

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Amoxicillin for Oral Suspension USP 125mg/5mL and 250mg/5mL.

Amoxicillin for Oral Suspension USP 125mg/5mL and 250mg/5mL is the generic equivalent to the reference listed drug product (RLD), Amoxicillin for Oral Suspension, 125mg/5 mL and 250mg/5mL respectively of Teva Pharmaceutical Industries and indicated in the treatment of infections due to susceptible βetalactamase-negative strains of the designated microorganisms.

According to IMS, the product has a market size of approximately $19 million for the twelve months ending July 2014. These ANDAs has been approved out of Unit XII, Semi-Synthetic Penicillin (SSP) formulation facility in Hyderabad, India.

Aurobindo now has a total of 195 ANDA approvals (169 Final approvals including 7 from Aurolife Pharma LLC and 26 Tentative approvals) from USFDA. 

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×